Screening of soy protein-derived hypotriglyceridemic di-peptides \textit{in vitro} and \textit{in vivo}

Nao Inoue$^{1,4\dagger}$, Koji Nagao$^{1\dagger}$, Kotaro Sakata$^1$, Naomi Yamano$^1$, Pathma Elgoda Ranawakage Gunawardena$^1$, Seo-Young Han$^1$, Toshiro Matsui$^2$, Toshihiro Nakamori$^3$, Hitoshi Furuta$^3$, Kiyoharu Takamatsu$^3$ and Teruyoshi Yanagita$^1$

Abstract

Background: Soy protein and soy peptides have attracted considerable attention because of their potentially beneficial biological properties, including antihypertensive, anticarcinogenic, and hypolipidemic effects. Although soy protein isolate contains several bioactive peptides that have distinct physiological activities in lipid metabolism, it is not clear which peptide sequences are responsible for the triglyceride (TG)-lowering effects. In the present study, we investigated the effects of soy protein-derived peptides on lipid metabolism, especially TG metabolism, in HepG2 cells and obese Otsuka Long-Evans Tokushima fatty (OLETF) rats.

Results: In the first experiment, we found that soy crude peptide (SCP)-LD3, which was prepared by hydrolyze of soy protein isolate with endo-type protease, showed hypolipidemic effects in HepG2 cells and OLETF rats. In the second experiment, we found that hydrophilic fraction, separated from SCP-LD3 with hydrophobic synthetic absorbent, revealed lipid-lowering effects in HepG2 cells and OLETF rats. In the third experiment, we found that Fraction-C (Frc-C) peptides, fractionated from hydrophilic peptides by gel permeation chromatography-high performance liquid chromatography, significantly reduced TG synthesis and apolipoprotein B (apoB) secretion in HepG2 cells. In the fourth experiment, we found that the fraction with 0.1% trifluoroacetic acid, isolated from Frc-C peptides by octadecylsilyl column chromatography, showed hypolipidemic effects in HepG2 cells. In the final experiment, we found that 3 di-peptides, Lys-Ala, Val-Lys, and Ser-Tyr, reduced TG synthesis, and Ser-Tyr additionally reduced apoB secretion in HepG2 cells.

Conclusion: Novel active peptides with TG-lowering effects from soy protein have been isolated.

Background

In industrialized countries, lifestyle-related diseases such as hyperlipidemia, arteriosclerosis, diabetes mellitus, and hypertension are widespread and increasingly prevalent, thus contributing to the increases in cardiovascular morbidity and mortality [1,2]. Accompanied by the rapid increase in the number of elderly people, this increase in lifestyle-related diseases becomes important not only medically, but also socioeconomically. A clustering of metabolic disorders in an individual, defined as metabolic syndrome, is known to increase cardiovascular morbidity and mortality. Although the pathogenesis of metabolic syndrome is complicated and the precise details of its underlying mechanisms are not known, lipid abnormality is now proposed as a feature of metabolic syndrome along with insulin resistance [1-3]. Many studies have suggested that the quality of dietary proteins can be an important modulator of the risks associated with this syndrome [4-7].

In general, plant protein intake is inversely related to the risk of hypertension and cardiovascular disease [4-7]. For example, several studies have shown that dietary soy protein reduces cholesterol and triglyceride (TG) levels and lowers blood pressure in animals and humans [4-9]. Because it has been reported that peptides or
protein hydrolysates show greater bioactivities than intact proteins or amino acid mixtures [10,11], bioactive peptides have been produced in vitro through chemical or enzymatic hydrolysis of several food proteins, in order to modify and improve the physiological functions of dietary proteins [11,12]. Bioactive peptides are prepared from both plant and animal sources, with the antihypertensive peptides IAP and VY and the hypocholesterolemic peptide IIAEK derived from wheat gliadin, sardine muscle, and bovine milk α-lactoglobulin, respectively [13-17]. For soy protein, several bioactive peptides, including the hypocholesterolemic peptide LPYPR, antihypertensive peptide NWGPLV, antioxidant peptide LLPHH, and anti-obese peptide VRIRLQRFNKRS, were derived from its major constituents, glycinin and β-conglycinin (BCG) [18-21]. Of the limited number of peptides reported to have hypotriglyceridemic activities, VVYP, VYP, and VTL were identified in hydrolyzed globin from animal blood [22].

In the present study, we investigated the effects of soy protein-derived peptides on hepatic lipid metabolism, especially TG metabolism, both in vitro and in vivo. We used human hepatoma HepG2 cells, the most suitable and accessible human-derived cells that retain many of the biochemical functions of human liver parenchymal cells [23], for the in vitro study. For the in vivo study, Otsuka Long-Evans Tokushima fatty (OLETF) rats, which develop a syndrome with multiple metabolic and hormonal disorders that shares many features of human obesity, were used. OLETF rats exhibit hyperphagia, owing to the lack of cholecystokinin receptors; as a result, they become obese and develop hyperlipidemia, fatty liver, and diabetes [24-26].

**Materials and methods**

**Preparation of soy peptides**

Preparation of soy crude peptides (SCP)-LD3 was performed by hydrolyze of soy protein isolate with endo-type protease derived from Bacillus sp. and fractionation with centrifugation [27]. SCP-LD3 was separated into 2 fractions (hydrophobic fraction and hydrophilic fraction) on the basis of hydrophobicity by using hydrophobic synthetic absorbent (DIAION HP21; Mitsubishi Chemical Corporation, Tokyo, Japan). The amino acid composition of SCP-LD3, hydrophobic fraction, and hydrophilic fraction was analyzed with an automatic amino acid analyzer; results are shown in Table 1. Hydrophilic fraction was further fractionated by gel permeation chromatography-high performance liquid chromatography (GPC-HPLC, Bio-Rad Superdex Peptide HR10/30 column, 30% CH3CN/0.1% trifluoroacetic acid (TFA), 0.3 mL/min), and di- or tri-peptide fractions were collected at an elution time ranging from 45 to 75 min (Figure 1; Fraction A, Frc-A, 45-55 min; Fraction B, Frc-B, 55-65 min; Fraction C, Frc-C, 65-75 min). Then, 2 peptide fractions (0% CH3CN/0.1% TFA and 20% CH3CN/0.1% TFA fractions) were obtained by octadecylsilyl (ODS) open-column chromatography (20 × 60 mm) from Frc-C peptides. Finally, 0% CH3CN/0.1% TFA fraction peptides were separated by reversed-phase HPLC (COSMOSIL 5C18-AR-II column; Nakalai tesque, Kyoto, Japan), and 7 di-peptides (Figure 2; Table 1 Amino acid composition of soy peptides)

| Amino acid | Soy crude peptide-LD3 | Hydrophobic peptide | Hydrophilic peptide |
|-----------|-----------------------|---------------------|---------------------|
| Val       | 3.78                  | 4.84                | 4.00                |
| Ile       | 3.81                  | 5.98                | 3.15                |
| Leu       | 8.00                  | 5.41                | 8.61                |
| Lys       | 6.20                  | 5.35                | 7.15                |
| Met       | 1.50                  | 1.47                | 1.00                |
| Phe       | 4.86                  | 8.20                | 2.80                |
| Thr       | 4.07                  | 3.45                | 3.84                |
| Trp       | -                     | -                   | -                   |
| His       | 2.97                  | 3.05                | 2.99                |
| Tyr       | 4.19                  | 4.87                | 2.32                |
| Cys       | 1.08                  | 1.50                | 1.13                |
| Asx       | 12.11                 | 11.33               | 12.62               |
| Glx       | 20.38                 | 13.28               | 27.14               |
| Pro       | 5.52                  | 8.23                | 4.73                |
| Gly       | 3.82                  | 3.94                | 4.12                |
| Ser       | 5.56                  | 4.25                | 5.52                |
| Ala       | 4.10                  | 2.94                | 4.42                |
| Arg       | 8.11                  | 8.71                | 7.66                |

Tryptophan content could not be determined under the present experimental condition.

![Figure 1](http://www.lipidworld.com/content/10/1/85)
Ala-Leu, Ala-Tyr, Ala-Val, Leu-Val, Lys-Ala, Ser-Tyr, and Val-Lys) were identified. These di-peptides, except Leu-Val, could be synthesized using a Fmoc solid-phase synthesis method according to the manufacturer’s instructions (Kokusan Chemicals, Osaka, Japan). The sequence of the di-peptides was confirmed on a PPSQ-21 amino acid sequencer (Shimadzu Co., Kyoto, Japan).

Cell culture
HepG2 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 100 units/mL penicillin and 100 μg/mL streptomycin and supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO₂. At approximately 70-80% confluence, the medium was preincubated with 1% bovine serum albumin (BSA)-DMEM with 0.5 mM oleic acid for 24 h. The fatty acid-BSA complex was prepared as described by Van Harken et al [28]. The cellular protein concentration was determined using the method of Lowry et al [29] or the bicinchoninic acid method [30]. To measure cytotoxicity, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) activity was determined using a MTT Cell Growth Kit (CHEMICON International, Inc., Temecula, CA, U.S.A.); and after 24-h incubation with 1-10 mg/mL of the soy peptides, the MTT activity of HepG2 cells was unaffected in all experiments (data not shown).

Measurement of cellular TG synthesis
To evaluate the effects of the peptides on cellular TG synthesis, HepG2 cells were preincubated with 1% BSA-DMEM with 0.5 mM oleic acid for 24 h and then incubated with experimental medium (Control: 1% BSA-DMEM; Peptides: 1% BSA-DMEM with 1-10 mg/mL of the soy peptides) containing 18.5 KBq [1-14C] acetate (American Radiolabeled Chemicals, St. Louis, MO, USA) for 24 h. After incubation, cells were washed once and collected in 2 mL of phosphate-buffered saline using a rubber policeman. Cells were thawed and homogenized with a sonicator (Sonifier 250TM; Branson Ultrasonic Co., CT, USA) before analysis. Total lipids in the cells were extracted and purified by the method of Bligh and Dyer [31], then radioactivities were measured by a liquid scintillation counter (Wallic System 1410; Pharmacia, Uppsala, Sweden). The lipids were fractionated using thin-layer chromatography (TLC) in a solvent mixture of petroleum ether:diethyl ether:acetate (82:18:1, v/v/v). After separation with TLC, the radioactivities of the lipid fractions were quantitated with a bio-imaging analyzer (BAS1000; Fuji Photo Film, Kanagawa, Japan). Activity of TG synthesis was calculated as “cpm per mg protein” and represented as “% of control” in figures.

Measurement of apolipoprotein B100 secretion
To evaluate the effects of the di-peptides on apolipoprotein B100 (apoB100) secretion, HepG2 cells were preincubated with 1% BSA-DMEM with 0.5 mM oleic acid for 24 h and further incubated with experimental medium (Control: 1% BSA-DMEM; Peptides: 1% BSA-DMEM with 5 mg/mL di-peptides) for 24 h. At the end of the experiment, the media were harvested for the measurement of apoB100 levels, and the cells were used for determination of cellular protein levels. ApoB100 levels in the culture media were quantitated using the ApoB Microwell ELISA Assay Kit (AlerCHEK).

Animals and diets
All aspects of the animal experiment were conducted according to the guidelines provided by the ethical committee of experimental animal care at Saga University. Male OLETF rats aged 4 weeks were provided by the Tokushima Research Institute (Otsuka Pharmaceutical, Tokushima, Japan). The rats were housed individually in metal cages in a temperature-controlled room (24°C) under a 12-h light/dark cycle. In the first animal experiment, the rats were assigned to 1 of 2 groups (6 rats each), and were fed 1 of 2 diets: (i) a semi-synthetic diet containing (in weight %) casein, 20; corn oil, 7; corn-starch, 15; vitamin mixture (AIN-76™), 1; mineral mixture (AIN-76™), 3.5; DL-methionine, 0.3; choline bitartrate, 0.2; cellulose, 5; and sucrose, 48 (control diet, Con); (ii) a semi-synthetic diet containing (in weight %) SCP-LD3, 19.1; corn oil, 7; cornstarch, 15; vitamin mixture (AIN-76™), 1; mineral mixture (AIN-76™), 3.5; DL-methionine, 0.3; choline bitartrate, 0.2; cellulose, 5; and sucrose, 48.9 (soy peptide diet, SoyPep) for 2 weeks. In the second animal experiment, the rats were assigned to 1 of 3 groups (6 rats each) and were fed 1 of the following 3 diets: (i)

![Figure 2 Reversed phase-high performance liquid chromatography elution profile of 0% CH₃CN/0.1%TFA fraction peptides on COSMOSIL 5C₁₈-AR-II column and identification of di-peptides.](http://www.lipidworld.com/content/10/1/85)
control diet; (ii) soy peptide diet; and (iii) a semi-synthetic diet containing (in weight %) hydrophilic peptide, 11.85; casein, 10; corn oil, 7; cornstarch, 15; vitamin mixture, 1; mineral mixture, 3.5; DL-methionine, 0.3; choline bitartrate, 0.2; cellulose, 5; and sucrose, 46.15 (hydrophilic peptide diet) for 4 weeks. Basal semi-synthetic diets were prepared according to recommendations of the AIN-76 [32].

Measurement of TG levels in serum and liver
All rats were killed by aortic exsanguination under diethyl ether anesthesia, and the liver was excised for analysis. The serum was separated from the blood, and serum TG levels were measured using a commercial enzyme assay kit (Wako Pure Chemicals, Tokyo, Japan). Hepatic lipid was extracted according to the method of Folch et al. [33], and the TG concentration was measured by the method of Fletcher [34].

Preparation of hepatic subcellular fractions
A piece of liver from each rat was homogenized in 6 volumes of a 0.25 M sucrose solution containing 1 mM ethylenediaminetetraacetic acid in a 10 mM Tris-HCl buffer (pH 7.4). After the nuclear fraction was precipitated, the supernatant was centrifuged at 10,000 x g for 10 min at 4°C to obtain mitochondrial fractions. The resulting supernatant was recentrifuged at 125,000 x g for 60 min to precipitate microsomes, and the remaining supernatant constituted the cytosol fraction. The protein concentration was determined according to the method of Lowry et al. [29], with BSA used as the standard.

Assays of hepatic enzyme activity
The enzyme activity of phosphatidate phosphohydrolase (PAP) [35], fatty acid synthase (FAS) [36], malic enzyme [37], glucose 6-phosphate dehydrogenase (G6PDH) [38], and carnitine palmitoyltransferase (CPT) [39] was determined as described elsewhere.

Statistical analysis
All values are expressed as mean ± SE. Data were analyzed by student t-test to assess differences between 2 groups. To assess differences between 3 groups, data were analyzed by 1-way ANOVA, and all differences were analyzed by the Tukey-Kramer post-hoc test (KaleidaGraph, Synergy Software, Reading, PA). Differences were considered significant at $P < 0.05$.

Results and discussion
The liver is the pivotal organ concerned with lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome and is emerging as the most common liver disease worldwide [40-42]. NAFLD is the preferred term used to describe the spectrum of liver damage, ranging from hepatic steatosis to steatohepatitis, liver fibrosis, and cirrhosis. Most liver-related morbidity and mortality events are associated with the development of cirrhosis. Cirrhosis is most likely to occur in individuals who have progressed from hepatic steatosis to steatohepatitis. Although the processes through which steatohepatitis evolves from hepatic steatosis are not fully understood, it is necessary to develop effective therapies for the treatment of NAFLD, and the discovery of nutrients that reduce the risk of NAFLD would be useful. We previously discovered novel hypolipidemic dietary components such as functional lipids and phytochemicals by in vitro (HepG2 cells) and in vivo (OLETF rats) evaluation [43-47].

Effects of SCP-LD3 on lipid metabolism in HepG2 cells and OLETF rats
In the first part of the current study, we evaluated the effects of SCP-LD3 treatment on TG synthesis in HepG2 cells. As shown in Figure 3A, incorporation of $[1-^{14}C]$ acetate into the cellular TG fraction was significantly lowered by SCP-LD3 treatment. These results suggest that SCP-LD3 has the ability to normalize lipid abnormalities possibly through the suppression of TG synthesis in hepatocytes. Next, we evaluated the effects of SCP-LD3 on lipid metabolism in OLETF rats. As shown in Figure 3B, 2-week feeding of SCP-LD3 alleviated the obesity-induced TG accumulation in the liver of OLETF rats without significant alterations in other growth parameters such as food intake (control, 29.2 ± 0.6 g/day; SCP-LD3, 29.0 ± 0.6 g/day) and final body weight (control, 539 ± 12 g; SCP-LD3, 531 ± 17 g). Additionally, serum TG level was also lowered by SCP-LD3 feeding in OLETF rats (control, 251...
± 40 mg/dL; SCP-LD3, 143 ± 21 mg/dL, \( P < 0.05 \)). These results indicate that SCP-LD3 has TG-lowering properties, which led us to perform further isolation and identification of hypolipidemic peptide sequences from this peptide during subsequent experiments.

**Effects of hydrophobic and hydrophilic fractions on lipid metabolism in HepG2 cells and OLETF rats**

Several reports have suggested that the amino acid composition of dietary proteins and peptides influences their bioactivities [11]. It has been reported that high amounts of histidine and hydrophobic amino acids contribute to antioxidant potency and that hydrophobic peptides can bind bile acids, thereby enhancing fecal steroid excretion [20,48-50]. In the second part of the current study, we evaluated the effects of hydrophobic and hydrophilic fractions, separated from SCP-LD3 with hydrophobic synthetic absorbent, on TG synthesis in HepG2 cells. As shown in Table 1, the hydrophobic fraction was found to contain a higher amount of phenylalanine, whereas the hydrophilic fraction contained a higher amount of glutamine compared to SCP-LD3. In HepG2 cells, incorporation of [1-14C] acetate into the cellular TG fraction was significantly and dose-dependently lowered by hydrophilic fraction treatment (Figure 4A). In the next in vivo experiment, we evaluated the effects of the hydrophilic fraction on lipid metabolism in OLETF rats. Though there was no significant alteration in growth parameters (Table 2), feeding of the hydrophilic fraction alleviated hepatomegaly and hepatic TG accumulation in OLETF rats (Table 2, Figure 4B). Moreover, despite the fact that the degree of supplementation with the hydrophilic fraction in the diet (substituted for 10% casein) was half that of SCP-LD3 (substituted for 20% casein), the TG-lowering effects of these 2 diets were almost the same. In agreement with the in vitro study, the TG-lowering effects were attributable to the suppression of fatty acid synthesis (represented by lowered activities of FAS, G6PDH, and malic enzyme) and TG synthesis (represented by lowered PAP activity) in the liver of OLETF rats.

**Effects of peptides fractionated by GPC-HPLC on TG synthesis and apoB100 secretion in HepG2 cells**

It has been shown that short peptides, mostly di-, tri-, and tetra-peptides, are absorbed more rapidly than free amino acids and that short peptides are absorbed intact by specific peptide transporters such as PepT1 and PepT2 into the blood circulation and transported to target organs [51-54]. Intact absorption of the hypotensive dipeptide Val-Tyr, for example, was confirmed in rats and humans [55-57]. In the third part of the current study, we evaluated the effects of di- or tri-peptide fractions, separated from the hydrophilic fraction with GPC-HPLC (Figure 1), on TG synthesis in HepG2 cells. As shown in Figure 5A, all 3 fractions lowered the incorporation of [1-14C] acetate into the cellular TG fraction significantly and dose-dependently. It is known that blood apoB100 level is positively correlated with the incidence of coronary heart disease and that enhanced secretion of apoB100 by the liver is a biomarker of hepatic lipid abnormality [58-60]. Therefore, dietary components that control the rate of apoB100 secretion by the liver are of great interest [61-63]. In the current study, we evaluated the effects of Frc-B and Frc-C treatment on apoB100 secretion from HepG2 cells. Our results show that Frc-C treatment, but not Frc-B treatment, induced a 33% reduction of apoB100 secretion compared with the control medium (Figure 5B).

**Effects of peptides fractionated by ODS column chromatography on TG synthesis and apoB100 secretion in HepG2 cells**

In the fourth part of the current study, we evaluated the effects of peptide fractions, separated from the Frc-C peptide with ODS column chromatography, on TG synthesis and apoB100 secretion in HepG2 cells. Our results show that 0% CH3CHCN/0.1% TFA fraction lowered both TG synthesis and apoB100 secretion, but 20% CH3CHCN/0.1% TFA fraction lowered only TG synthesis, in HepG2 cells (Figure 6A, B).

**Effects of synthesized di-peptides on TG synthesis and apoB100 secretion in HepG2 cells**

Finally, 0% CH3CN/0.1% TFA fraction peptides were separated by reverse-phase HPLC, where by 7 di-peptides were identified (Figure 2). Six di-peptides (Ala-Leu, Ala-Tyr, Ala-Val, Lys-Ala, Ser-Tyr, and Val-Lys), but not Leu-Val, could be synthesized, and we evaluated the
The effects of these di-peptides on TG synthesis and apoB100 secretion in HepG2 cells. We found that 3 di-peptides, Ser-Tyr, Val-Lys, and Lys-Ala, reduced TG synthesis (Figure 7A), and Ser-Tyr additionally reduced apoB secretion (Figure 7B) in HepG2 cells. The presence of 3 di-peptide sequences in the amino acid sequence of soybean components such as glycinin, the BCG alpha subunit (BCG-α), the BCG alpha prime subunit (BCG-α’), the BCG beta subunit (BCG-β), the trypsin inhibitor, and lipoxygenase is shown in Table 3. The presence of the Ser-Tyr sequence is recognized in the amino acid sequence of glycinin, BCG-α, BCG-α’, BCG-β, and lipoxygenase. The presence of the Val-Lys sequence is recognized in the amino acid sequence of glycinin, the trypsin inhibitor, and lipoxygenase. The presence of the Lys-Ala sequence is recognized in the amino acid sequence of glycinin, BCG-α, BCG-α’, BCG-β, the trypsin inhibitor, and lipoxygenase. Because of the suppressive effects on both lipogenesis and apoB100 secretion in HepG2 cells and the frequent presence in the amino acid sequence of major soybean components, we speculate that Ser-Tyr is the most effective TG-lowering constituent of soy protein isolate-derived peptides.

**Table 2** Effects of dietary soy peptides on growth parameters and activities of hepatic triglyceride metabolism-related enzymes in Otsuka Long-Evans Tokushima fatty rats

|                          | Control          | Soy crude peptide-LD3 | Hydrophilic peptide |
|--------------------------|------------------|------------------------|---------------------|
| Initial body weight (g)  | 465 ± 11         | 467 ± 7                | 463 ± 9             |
| Final body weight (g)    | 558 ± 10         | 554 ± 7                | 550 ± 8             |
| Food intake (g)          | 743 ± 3          | 740 ± 8                | 738 ± 10            |
| Liver weight (g/100 g b.w.) | 3.45 ± 0.05³     | 3.14 ± 0.05³           | 3.16 ± 0.06³        |
| Hepatic enzyme activity (nmol/min/mg protein) |                   |                        |                     |
| FAS                      | 170 ± 0.7³       | 136 ± 0.8³             | 133 ± 1.3³          |
| G6PDH                    | 127 ± 7³         | 82.7 ± 4.2³            | 77.0 ± 5.2³         |
| Malic enzyme             | 115 ± 5³         | 79.0 ± 3.7³            | 86.5 ± 2.1³         |
| PAP                      | 173 ± 1.1³       | 145 ± 0.5³             | 148 ± 0.5³          |
| CPT                      | 5.16 ± 0.31      | 5.66 ± 0.25            | 5.42 ± 0.10         |

FAS, fatty acid synthase; G6PDH, glucose 6-phosphate dehydrogenase; PAP, phosphatidate phosphohydrolase; CPT, carnitine palmitoyltransferase.

Values are expressed as mean ± standard error of 6 rats.

Different superscript letters indicate a significant difference at $P < 0.05$.

**Conclusion**

We appear to have isolated novel active peptides with TG-lowering effects from soy protein, including Lys-Ala, Val-Lys, and Ser-Tyr, using *in vitro* and *in vivo* screening systems (Figure 8). The physiological properties of these isolates would be, at least in part, attributable to suppressed lipogenesis in the liver. Further studies are necessary to evaluate the effects of these 3 di-peptides on lipid abnormalities *in vivo* and to determine the lowest effective concentration.

---

**Figure 5** Effects of fractionated soy peptides (1 or 5 mg/mL) on triglyceride (TG) synthesis and apolipoprotein (Apo) B100 secretion in HepG2 cells. Values are expressed as mean ± standard error of 5 samples. Different letters indicate a significant difference at $P < 0.05$.

**Figure 6** Effects of fractionated soy peptides (5 mg/mL) on triglyceride (TG) synthesis and apolipoprotein (Apo) B100 secretion in HepG2 cells. Values are expressed as mean ± standard error of 5 samples. Different letters indicate a significant difference at $P < 0.05$. 

---

Inoue et al. *Lipids in Health and Disease* 2011, **10**:85
http://www.lipidworld.com/content/10/1/85

Page 6 of 10
Figure 7 Effects of synthesized di-peptides (5 mg/mL) on triglyceride (TG) synthesis and apolipoprotein (Apo) B100 secretion in HepG2 cells. Values are expressed as mean ± standard error of 5 samples. Different letters indicate a significant difference at $P < 0.05$.

### Table 3 Amino acid sequence of major components in soy protein

| Glycinin (Glycine max) [soybean] | Accession number |
|---------------------------------|-----------------|
| MGKFTLSLSICLSSACFASSSKLNCEOQNLLNLNAELEPHDFFERGGQGTQWNPQHPELCAGTVSKLLTNLRNGHLPQSYPRIIIAMIAQGKALQCPGCPETFE EPQESQNNRGRSQXQLQDQSHQKRIHFNEGVLWPIPVGPPYWTYNTDEPDWAASLLTSNINQLDSTTPRVYFLAPNGNPQETYM1MQQQXKSGKRQGQHQ QEEEEEESAGVSFSKHLAQSFTNDEDIAKLQGDPREDKVTVEGGLSISPVKQWQOEDEDEDEDEDSHPPPRPQHSGREDEDEDDEKRRPRPSQ GKRQEDQQOQDEDEDEEQQDNAQQRQREPERCETGQVNEINCLTLKHENARRPSRASYNFKANGRSTNLSTPLARQFQLSAQYVLYKLYNGY SYPYHVLNLNANSYYTVFTGQGTVNCQGNAVPFDEGLIRGQSVLVPNQFVAEQAJEQQFFYEVYKTHHNAVXSYDKVDFRAPELAVSYNLIQRSQSYVELYEILG WCGPLUNPESQSFQPVR | CAAA37044 |

| Beta-conglycinin alpha subunit (Glycine max) [soybean] | Accession number |
|--------------------------------------------------------|-----------------|
| MMRARFPLLVLGLVLASVSFSGAYWEKENPHHNCRCRCNREDSYRNCQACHARNLLKKVEEXEEECEGPRPRPQHIPEROPQQGEDEEQGEOPRPPPRPPQP RQEOGEQEEQHKHEEWHREIKHEKKGGQEEGQEQGREHPHQPQHIPHQEQQKSEQEEDIQDEKQEDEQCEGESSEQEPRPPHHKNNHPL NISKRFQTLNFLNYVRHLARQFQKQQQQQQLNNADRYILFENSFQKNTLPLPHHADAVIILNGLTVLNNRDERSLQNLGQSDLARLPQTGTYWYNNPDENILNRM LTAIPYKNGPRESFSFLSTTOAQQSYLGFSNFNLAEYSDYTDFKEEINVLFWGRLQEGGQQGGERIQLQESMVEQIKRELSTRAKSSRTSSEDKPNLRSRDIPSLNLKLGKL FEITPEKPQNLIDVLSDVWMDMNAFLHLHFNHSLKAVLNVIGEANIEVLIVELQGEOQQEPOELQERVRAYEQLSEQDIVIFAPUGYVMANSLNNLFAIGINAENQ QNNFNLPSKGDNDVSISQPSQYVLELFAGSADXENLRSQSESYVQDAPOQKKEGGNKRQGKPLSSILRFA | BAE64788 |

| Beta-conglycinin alpha prime subunit (Glycine max) [soybean] | Accession number |
|----------------------------------------------------------|-----------------|
| MMRARFPLLVLGLVLASVSFSGAYWEKENPHHNCRCRCNREDSYRNCQACHARNLLKKVEEXEEECEGPRPRPQHIPEROPQQGEDEEQGEOPRPPPRPPQP RQEOGEQEEQHKHEEWHREIKHEKKGGQEEGQEQGREHPHQPQHIPHQEQQKSEQEEDIQDEKQEDEQCEGESSEQEPRPPHHKNNHPL NISKRFQTLNFLNYVRHLARQFQKQQQQQQLNNADRYILFENSFQKNTLPLPHHADAVIILNGLTVLNNRDERSLQNLGQSDLARLPQTGTYWYNNPDENILNRM LTAIPYKNGPRESFSFLSTTOAQQSYLGFSNFNLAEYSDYTDFKEEINVLFWGRLQEGGQQGGERIQLQESMVEQIKRELSTRAKSSRTSSEDKPNLRSRDIPSLNLKLGKL FEITPEKPQNLIDVLSDVWMDMNAFLHLHFNHSLKAVLNVIGEANIEVLIVELQGEOQQEPOELQERVRAYEQLSEQDIVIFAPUGYVMANSLNNLFAIGINAENQ QNNFNLPSKGDNDVSISQPSQYVLELFAGSADXENLRSQSESYVQDAPOQKKEGGNKRQGKPLSSILRFA | BAE64303 |

| Beta-conglycinin beta subunit (Glycine max) [soybean] | Accession number |
|-------------------------------------------------------|-----------------|
| MMRARFPLLVLGLVLASVSFSGAYWEKENPHHNCRCRCNREDSYRNCQACHARNLLKKVEEXEEECEGPRPRPQHIPEROPQQGEDEEQGEOPRPPPRPPQP RQEOGEQEEQHKHEEWHREIKHEKKGGQEEGQEQGREHPHQPQHIPHQEQQKSEQEEDIQDEKQEDEQCEGESSEQEPRPPHHKNNHPL NISKRFQTLNFLNYVRHLARQFQKQQQQQQLNNADRYILFENSFQKNTLPLPHHADAVIILNGLTVLNNRDERSLQNLGQSDLARLPQTGTYWYNNPDENILNRM LTAIPYKNGPRESFSFLSTTOAQQSYLGFSNFNLAEYSDYTDFKEEINVLFWGRLQEGGQQGGERIQLQESMVEQIKRELSTRAKSSRTSSEDKPNLRSRDIPSLNLKLGKL FEITPEKPQNLIDVLSDVWMDMNAFLHLHFNHSLKAVLNVIGEANIEVLIVELQGEOQQEPOELQERVRAYEQLSEQDIVIFAPUGYVMANSLNNLFAIGINAENQ QNNFNLPSKGDNDVSISQPSQYVLELFAGSADXENLRSQSESYVQDAPOQKKEGGNKRQGKPLSSILRFA | BAE64306 |

| Trypsin inhibitor (Glycine max) [soybean] | Accession number |
|----------------------------------------|-----------------|
| MPTSWAGGGGLKGRGNSICPVTQLQYSEIFRTGKVSPGSGPQGIFTGPTLLEFABKPYCAESS KWWAKFVDNIEOKAVCGGPPQGHPQGTFSGTSQKSYKFGYKYLFCIICTGSGTCDLGRFDANEGG RRLNLTENHAFDIVPFEAISKVDGIIKSW | AAF87095 |

| Lipoxygenase (Glycine max) [soybean] | Accession number |
|------------------------------------|-----------------|
| MGFIFDGQKQIKTGVWLMPKVNLDNAITSGSKQVEHCTATVSLGGQSVLWGVQDITATSFLRNINSQULATQTGDGNGKVGKEVYKLEKHTPLPTLGARQDAFSIF FEAWDASFGIFAGIYFKMNTFDMFLWVLLIDHPHIQFVCSVWYNYFISYKNRFIVFNTYLPATAPPLLKYKREELLVRLDTGKFRQODRVIDYDYVNDGN PDGQDPRRILLGSSSYPRPRWRTRGRTREDNPSKPGGGEVPYRPPREDNFFHSQDSTFTGYKLSDHLVPLHFSআlopQRTYSEFSEDWFLSVYELGKSSPLTDLSDQSPQ ALKEFITEETDFLQGFPFHVVSHSKSDQGFDMEFPVEAVGFIGNPQFPPKSTLPLDTFLLYDSTTFQNLMEINMGQVTVEALSQRLFDYDAFIPYTLTR INSFAPKAKATIFIILFDKGLKTLPAKIELPHQIPDPGDNLGPSPATIVALDTTLAAKAVNINQGQHYLVSNLTHAMFPLEAITHNRSLSLVHKLYLPHY DTINNGIATLVQSLNADIGESQSLFIIQGQVYKKVSSVYKONVQTFALPDADYRALIEQETAPWMDGLRLEDYTHINGVYDDLQWEKCOYPTAAYVQQDT EQDTEQWAWKIEAKHGDLKIEKPKWPMKINQTEDLQSCISMSMTATXHATANIFQQYPGQGLNLNRPLPPRFLARRPAEGTPEDEMDVKVHKPAŁAYRITTIFKETL IDLSVLSEILSHASDEYLGERETTWWDKYAKALEAFRQGSKTLEGKIGARSSDSPLRNTRGVPQLYTTYLHRSSEELTFKGIIPSSISI |

Definition [source]/Accession number. Lys-Ala, KA; Ser-Tyr, SY; Val-lys, VK.
List of abbreviations
ApoB100: apolipoprotein B100; BCG: β-conglycinin; BSA: bovine serum albumin; CPT: carnitine palmitoyltransferase; DMEM: dulbecco’s modified eagle medium; FAS: fatty acid synthase; G6PDH: glucose 6-phosphate dehydrogenase; GPC: gel permeation chromatography; HPLC: high performance liquid chromatography; MTT: 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide; NAFLD: nonalcoholic fatty liver disease; ODS: octadecylsilyl; OLETF: Otsuka Long-Evans Tokushima fatty; PAP: phosphatidate phosphohydrolase; SCP: soy crude peptide; TFA: trifluoroacetic acid; TG: triglyceride; TLC: thin-layer chromatography.

Acknowledgements
This work was supported by a research grant from Fuji Foundation for Protein Research.

Author details
1Department of Applied Biochemistry and Food Science, Saga University, Saga 840-8502, Japan. 2Department of Bioscience and Biotechnology, Graduate School of Kyushu University, Fukuoka 812-8581, Japan. 3Fuji Oil Co, Osaka 598-8540, Japan. 4Graduate School of Agricultural Science, Tohoku University, Miyagi 981-8555, Japan.

Authors’ contributions
NI and KN made substantial contributions to the conception and design of the study, performing the experiment, assembly, analysis and interpretation of data and drafting the manuscript. KS, NY, PERG, SYH, TM and TN participated in experimental work and collection, assembly, analysis of data. HF, KT and TY contributed in planning of the experiment and in discussion of results. All authors read and approved the final manuscript.

Figure 8 Screening chart of lipid-lowering di-peptides from soy protein isolate.

Inoue et al. Lipids in Health and Disease 2011, 10:85
http://www.lipidworld.com/content/10/1/85
Page 8 of 10
Competing interests

The authors declare that they have no competing interests.

Received: 1 April 2011 Accepted: 22 May 2011 Published: 22 May 2011

References

1. Kisszab AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994, 74:761-811.
2. Formiguera X, Canton A. Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 2004, 18:1125-1146.
3. Nago K, Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
4. Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim Biophys Acta 2010, 1801:367-371.
5. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
6. Sintini CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutriceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. Atherosclerosis 2009, 203:8-17.
7. Elliott P, Stamler J, Dyer AR, Appel L, Dennis B, Kesteloot H, Ueshima H, Okuyama A, Chan Q, Garside DB, Zhou B. Association between protein intake and blood pressure: the INTERMAP Study. Arch Int Med 2006, 166:79-87.
8. Sakamoto M, Yoshida K, Yahiro M. Combined effects of dietary protein and fat on lipid metabolism in rats. J Nutr Sci Vitaminol (Tokyo) 1993, 39:333-345.
9. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
10. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
11. Erdmann K, Cheung BW, Schröder H. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
12. Shahidi F, Zhong Y. Properties of Histidine-Containing Peptides Designed from Peptide Hypertensive Model Rats. J Appl Toxicol 2000, 20:281-287.
13. Walker PA, Possmayer F. The 9cis, 11trans, 13cis iso-linolenic acid reduces apolipoprotein B secretion in HepG2 cells. J Nutr Sci Vitaminol (Tokyo) 2000, 46:169-175.
14. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
15. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
16. Erdmann K, Cheung BW, Schröder H. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
17. Elliott P, Stamler J, Dyer AR, Appel L, Dennis B, Kesteloot H, Ueshima H, Okuyama A, Chan Q, Garside DB, Zhou B. Association between protein intake and blood pressure: the INTERMAP Study. Arch Int Med 2006, 166:79-87.
18. Sakamoto M, Yoshida K, Yahiro M. Combined effects of dietary protein and fat on lipid metabolism in rats. J Nutr Sci Vitaminol (Tokyo) 1993, 39:333-345.
19. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
20. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
21. Erdmann K, Cheung BW, Schröder H. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
22. Elliott P, Stamler J, Dyer AR, Appel L, Dennis B, Kesteloot H, Ueshima H, Okuyama A, Chan Q, Garside DB, Zhou B. Association between protein intake and blood pressure: the INTERMAP Study. Arch Int Med 2006, 166:79-87.
23. Walker PA, Possmayer F. The 9cis, 11trans, 13cis iso-linolenic acid reduces apolipoprotein B secretion in HepG2 cells. J Nutr Sci Vitaminol (Tokyo) 2000, 46:169-175.
24. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
25. Inoue M, Nakamura Y, Nagaoka K, Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
26. Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim Biophys Acta 2010, 1801:367-371.
27. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
28. Nishii T, Hara H, Asano K, Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 2003, 133:2537-2602.
29. Nishii T, Hara H, Asano K, Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 2003, 133:2537-2602.
30. Kagawa K, Matsukata H, Fukuhama C, Watanabe Y, Fujino H. Globin digest, acidic protein hydrolysate, inhibits dietary hypertriglyceridemia and val-Val-Tyr-Pro, one of its constituents, possesses most superior effect. Life Sci 1996, 58:1745-1755.
31. Naga K, Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
32. Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim Biophys Acta 2010, 1801:367-371.
33. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
34. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
35. Inoue M, Nakamura Y, Nagaoka K, Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
36. Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim Biophys Acta 2010, 1801:367-371.
37. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
38. Nishii T, Hara H, Asano K, Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 2003, 133:2537-2602.
39. Kagawa K, Matsukata H, Fukuhama C, Watanabe Y, Fujino H. Globin digest, acidic protein hydrolysate, inhibits dietary hypertriglyceridemia and val-Val-Tyr-Pro, one of its constituents, possesses most superior effect. Life Sci 1996, 58:1745-1755.
40. Koba K, Liu JW, Bobik E Jr, Mills DE, Sugano M, Huang YS. Identification of an Angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. J Nutr 2000, 130:79-87.
41. Inoue M, Nakamura Y, Nagaoka K, Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
42. Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim Biophys Acta 2010, 1801:367-371.
43. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003, 14:55-59.
44. Nishii T, Hara H, Asano K, Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 2003, 133:2537-2602.
46. Arao K, Wang YM, Inoue N, Hirata J, Cha JY, Nagao K, Yanagita T: Dietary effect of pomegranate seed oil rich in 9cis,11trans,13cis conjugated linolenic acid on lipid metabolism in obese, hyperlipidemic OLETF Rats. *Lipids Health Dis* 2004; 3:24.

47. Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T: Effects of citrus auraptene (7-geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. *J Agric Food Chem* 2010, 58:9028-9032.

48. Pena-Ramos EA, Xiong YL, Arteaga GE: Fractionation and characterisation for antioxidant activity of hydrolysed whey protein. *J Sci Food Agric* 2004, 84:1908-1918.

49. Iwami K, Sakakibara H, Ibuki F: Involvement of post-digestion 'hydrophobic' peptides in plasma cholesterol-low ering effect of dietary plant proteins. *Agric Biol Chem* 1986, 50:1217-1222.

50. Making S, Nakashima H, Minami K, Moriyama R, Takao S: Bile acid-binding protein from soybean seed: isolation, partial characterization and insulin-stimulating activity. *Agric Biol Chem* 1988, 52:803-809.

51. Webb KE Jr: Intestinal absorption of protein hydrolysis products. *J Anim Sci* 1990, 68:3011-3022.

52. Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA: Expression cloning of a mammalian proton-coupled oligopeptide transporter. *Nature* 1994, 368:563-566.

53. Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, Leibach FH: Molecular cloning of PEP'T 2, a new member of the H+/peptide cotransporter family, from human kidney. *Biochim Biophys Acta* 1995, 1235:461-466.

54. Daniel H, Spanier B, Kottra G, Weitz D: From bacteria to man: archaic proton-dependent peptide transporters at work. *Physiology (Bethesda)* 2006, 21:93-102.

55. Matsui T, Tamaya K, Seki E, Ojaima K, Matsumoto K, Kawasaki T: Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. *Clin Exp Pharmacol Physiol* 2002, 29:204-208.

56. Matsui T, Tamaya K, Seki E, Ojaima K, Matsumoto K, Kawasaki T: Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. *Biol Pharm Bull* 2002, 25:1228-1230.

57. Matsui T, Imamura M, Oka H, Ojaima K, Kimoto K, Kawasaki T, Matsumoto K: Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. *J Pept Sci* 2004, 10:535-545.

58. Fong DG, Nehra V, Lindor KD, Buchman AL: Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology* 2000, 32:3-10.

59. Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K: Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production. *Am J Physiol Gastrointest Liver Physiol* 2009, 296:G1287-1298.

60. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Banse S, Barve S, McClain C: Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. *J Nutr Biochem* 2007, 18:184-195.

61. Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S: Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. *Lipids Health Dis* 2008, 7:38.

62. Inoue N, Yamano N, Sakata K, Nagao K, Hama Y, Yanagita T: The sulfated polysaccharide porphyran reduces apolipoprotein B100 secretion and lipid synthesis in HepG2 cells. *Biosci Biotechnol Biochem* 2009, 73:447-449.

63. Inoue N, Yamano N, Sakata K, Arai K, Kobayashi T, Nagao T, Shimada Y, Nagao K, Yanagita T: Linoleic acid-menthyl ester reduces the secretion of apolipoprotein B100 in HepG2 cells. *J Osteo Sci* 2009, 58:171-175.